The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastases in mice.
A study was made of the effect of various cytotoxic drugs on the ability of i.v.-injected KHT sarcoma cells to form lung colonies in syngeneic C3H mice. Some enhancement of the number of lung colonies following an i.v. injection was seen following pretreatment of the mice with actinomycin D and mithramycin, while pretreatment with vinblastine, bleomycin, methotrexate, cytosine arabinoside, or 5-fluorouracil had little or no effect on lung colony formation. Pretreatment of the mice with cyclophosphamide, however, greatly increased lung colony formation (by a factor of approximately 100). This enhancement in lung colony formation was maximal when the drug was given 24 hr prio to the injection of tumor cells, but was seen as early as 2 hr and persisted as long as 8 weeks prior to the tumor cell injection. The degree of enhancement of lung colony formation was related to the dose of cyclophosphamide and was present in weaning as well as adult mice. This enhancement was not significantly reversed by anticoagulation with either aspirin or warfarin. Immunosuppression by whole-body irradiation did not affect the number of lung colonies seen in cyclophosphamide-treated mice. The mechanism by which cyclophosphamide enhances metastatic tumor growth within the lung is not known. The major effect, however, does not appear to be mediated  either by specific immunological or clotting factors.
D000367:Age Factors; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001241:Aspirin / Q000494:pharmacology; D003520:Cyclophosphamide / Q000009:adverse effects*; D003609:Dactinomycin / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D007165:Immunosuppression Therapy; D008175:Lung Neoplasms; D051379:Mice; D008809:Mice, Inbred C3H; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D008926:Plicamycin / Q000009:adverse effects; D011830:Radiation Effects; D012513:Sarcoma, Experimental; D014859:Warfarin / Q000494:pharmacology
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014859:Warfarin; D003520:Cyclophosphamide; D008926:Plicamycin; D001241:Aspirin